Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Vertex to Announce Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
04:15pm, Thursday, 11'th Jul 2024
KING OF PRUSSIA, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
12:31pm, Tuesday, 09'th Jul 2024
Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
05:45am, Friday, 05'th Jul 2024
Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
08:41am, Thursday, 27'th Jun 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
04:12am, Tuesday, 25'th Jun 2024
Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insul
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differenti
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people w
Vertex Acquires Artificial Intelligence Tax Capabilities from Ryan, LLC
07:05am, Wednesday, 12'th Jun 2024
KING OF PRUSSIA, Pa., June 12, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today the acquisition
Vertex Shares Rising on Expanded Therapy Offerings
12:59pm, Tuesday, 11'th Jun 2024
Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union a
Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
05:37pm, Tuesday, 04'th Jun 2024
Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's inno
3 Overlooked Tech Stocks Aiming for a 10X Surge
12:00pm, Saturday, 01'st Jun 2024
The Nasdaq hit a record high after Fed chairman Jerome Powell reassured investors with his comment. The central bank's next interest rate move is more likely not to be a hike, even though inflation ha
Vertex to Present at Upcoming Conferences
04:15pm, Thursday, 30'th May 2024
KING OF PRUSSIA, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that management will present at the following investor
Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts
11:50am, Thursday, 30'th May 2024
Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
09:45am, Sunday, 26'th May 2024
Vertex has achieved significant growth in recent years, but things have slowed lately. The company has many potential catalysts that could accelerate its growth rate.
